Rapidly Advancing
AI-Built Next-Generation
Therapies
Potential Indications
Potential IndicationsEarly Stage
Early StageLead Optimization
Lead OptimizationCandidate Selection
Candidate SelectionIND-Enabling
IND-Enabling
AIGEN Sciences Owned
NSCLC, PDAC, CRC
AIG01 is a highly potent and selective oral SOS1 inhibitor targeting pan-KRAS cancers, including NSCLC, PDAC, and CRC. By disrupting the SOS1–KRAS interaction, AIG01 blocks KRAS activation and enhances the efficacy of KRAS G12C inhibitors like Sotorasib. It shows strong synergy in KRAS and EGFR mutant models and overcomes acquired resistance in G12C-driven cancers.
USP1
BRCA1 Deficient Solid Cancer
BRCA1 Deficient
Solid Cancer
AIG07 is a selective, allosteric USP1 inhibitor designed to treat BRCA-deficient and other HRD-positive tumors. By preventing USP1-mediated deubiquitination of FANCD2 and PCNA, AIG07 disrupts DNA repair pathways, inducing synthetic lethality. It shows potent synergy with PARP inhibitors like Olaparib and addresses a key unmet need in patients resistant to current HRD therapies.
BRCA1 Deficient
Solid Cancer
AIG13
AIG13 targets Poly(ADP-ribose) glycohydrolase (PARG), a key enzyme in DNA damage recovery. By inhibiting PARG, AIG13 disrupts the balance of PARylation dynamics essential for effective DNA repair, inducing synthetic lethality in homologous recombination-deficient tumor cells. This approach offers a mechanistically distinct alternative to PARP inhibition, with potential to overcome or bypass PARP resistance mechanisms.
KRAS (G12C ON)
NSCLC, PDAC, CRC
NSCLC, PDAC, CRC
AIG14
AIG14 directly targets the active, GTP-bound form of KRAS G12C (“ON” state), aiming to overcome limitations of current inhibitors that rely on trapping the inactive GDP-bound form. By selectively disrupting KRAS signaling in its active state, AIG14 has the potential to deliver deeper and more sustained pathway inhibition, particularly in tumors that rapidly cycle KRAS or develop resistance to conventional G12C inhibitors.
Cancer
AIG18
AIG18 inhibits METTL3, an m6A methyltransferase involved in RNA epitranscriptomic regulation. By modulating m6A marks on cancer-relevant transcripts, AIG18 impairs oncogenic RNA processing, stability, and translation. This represents a novel strategy to target cancer-driving gene expression programs post-transcriptionally, with the potential to affect a broad range of tumor types.
Undisclosed 10 Targets
Undisclosed
Undisclosed
Undisclosed Multiple Stages
Partnered Programs
Payload - Linker ADC
Undisclosed
Undisclosed
Undis
closed
Undisclosed 3 Targets
Undisclosed
Undisclosed
Undisclosed